These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38645474)

  • 21. Clinical utility of hypo- and hyperpigmentation of skin in diffuse cutaneous systemic sclerosis.
    Solanki KK; Hor C; Chang WSJ; Frampton C; White DHN
    Int J Rheum Dis; 2017 Jun; 20(6):767-773. PubMed ID: 28261995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis.
    Otteby KE; Holmquist E; Saxne T; Heinegård D; Hesselstrand R; Blom AM
    Arthritis Res Ther; 2013; 15(6):R215. PubMed ID: 24330664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
    Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
    Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
    Domsic RT; Medsger TA; Gao S; Laffoon M; Huang S; Wisniewski S; Spino C; Steen V; Lafyatis R; Khanna D
    Rheumatology (Oxford); 2023 Apr; 62(4):1543-1551. PubMed ID: 36031807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
    Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
    Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum concentration of angiopoietin-like protein 4 in patients with systemic sclerosis.
    Żółkiewicz J; Stochmal A; Zaremba M; Hoffmann A; Czuwara J; Rudnicka L
    Pol Merkur Lekarski; 2021 Feb; 49(289):28-31. PubMed ID: 33713089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study.
    Peytrignet S; Manning J; Wragg E; Moore T; Samaranayaka M; Dinsdale G; Herrick AL
    Scand J Rheumatol; 2019 May; 48(3):230-234. PubMed ID: 30394164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.
    Amjadi S; Maranian P; Furst DE; Clements PJ; Wong WK; Postlethwaite AE; Khanna PP; Khanna D;
    Arthritis Rheum; 2009 Aug; 60(8):2490-8. PubMed ID: 19644851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
    Lescoat A; Huang S; Carreira PE; Siegert E; de Vries-Bouwstra J; Distler JHW; Smith V; Del Galdo F; Anic B; Damjanov N; Rednic S; Ribi C; Bancel DF; Hoffmann-Vold AM; Gabrielli A; Distler O; Khanna D; Allanore Y;
    JAMA Dermatol; 2023 Aug; 159(8):837-847. PubMed ID: 37378994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial.
    Ebata S; Oba K; Kashiwabara K; Ueda K; Uemura Y; Watadani T; Fukasawa T; Miura S; Yoshizaki-Ogawa A; Yoshihide A; Yoshizaki A; Sato S
    Rheumatology (Oxford); 2022 Nov; 61(11):4364-4373. PubMed ID: 35136981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis.
    Bellocchi C; Ying J; Goldmuntz EA; Keyes-Elstein L; Varga J; Hinchcliff ME; Lyons MA; McSweeney P; Furst DE; Nash R; Crofford LJ; Welch B; Goldin JG; Pinckney A; Mayes MD; Sullivan KM; Assassi S
    Arthritis Rheumatol; 2021 Apr; 73(4):660-670. PubMed ID: 33131208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis.
    Yamaguchi Y; Ono J; Masuoka M; Ohta S; Izuhara K; Ikezawa Z; Aihara M; Takahashi K
    Br J Dermatol; 2013 Apr; 168(4):717-25. PubMed ID: 23110679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity.
    Lofgren S; Hinchcliff M; Carns M; Wood T; Aren K; Arroyo E; Cheung P; Kuo A; Valenzuela A; Haemel A; Wolters PJ; Gordon J; Spiera R; Assassi S; Boin F; Chung L; Fiorentino D; Utz PJ; Whitfield ML; Khatri P
    JCI Insight; 2016 Dec; 1(21):e89073. PubMed ID: 28018971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.
    Silva C; Solanki KK; White DHN
    Rheumatol Immunol Res; 2022 Jun; 3(2):84-89. PubMed ID: 36465326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.
    Dobrota R; Maurer B; Graf N; Jordan S; Mihai C; Kowal-Bielecka O; Allanore Y; Distler O;
    Ann Rheum Dis; 2016 Oct; 75(10):1743-8. PubMed ID: 27016052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan.
    Kuwana M; Hasegawa M; Fukue R; Shirai Y; Ishikawa O; Endo H; Ogawa F; Goto D; Kawaguchi Y; Sato S; Ihn H; Takehara K
    Mod Rheumatol; 2021 Mar; 31(2):386-393. PubMed ID: 32552202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skin fibrosis correlates with circulating thyrotropin levels in systemic sclerosis: translational association with Hashimoto's thyroiditis.
    Bagnato GL; Roberts WN; Fiorenza A; Arcuri C; Certo R; Trimarchi F; Ruggeri RM; Bagnato GF
    Endocrine; 2016 Feb; 51(2):291-7. PubMed ID: 25994300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
    Namas R; Tashkin DP; Furst DE; Wilhalme H; Tseng CH; Roth MD; Kafaja S; Volkmann E; Clements PJ; Khanna D;
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS).
    Zheng B; Hudson M; Wang M; Baron M;
    Arthritis Res Ther; 2020 Jun; 22(1):132. PubMed ID: 32503616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.